Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients.

Wang Y, Hu X, Liu X, Wang Z.

Ther Clin Risk Manag. 2016 Jul 15;12:1113-31. doi: 10.2147/TCRM.S112236. eCollection 2016.

2.

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.

Fioretto P, Mansfield TA, Ptaszynska A, Yavin Y, Johnsson E, Parikh S.

Drugs Aging. 2016 Jul;33(7):511-22. doi: 10.1007/s40266-016-0382-1.

3.

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.

Araki E, Onishi Y, Asano M, Kim H, Ekholm E, Johnsson E, Yajima T.

J Diabetes Investig. 2016 Jul;7(4):555-64. doi: 10.1111/jdi.12453. Epub 2016 Jan 22.

4.

Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR.

Kuecker CM, Vivian EM.

Diabetes Metab Syndr Obes. 2016 Feb 23;9:25-35. doi: 10.2147/DMSO.S81565. eCollection 2016. Review.

5.

The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.

de Wit HM, Te Groen M, Rovers MM, Tack CJ.

Br J Clin Pharmacol. 2016 Jul;82(1):301-14. doi: 10.1111/bcp.12925. Epub 2016 Apr 22. Review.

PMID:
26935973
6.

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.

Shyangdan DS, Uthman OA, Waugh N.

BMJ Open. 2016 Feb 24;6(2):e009417. doi: 10.1136/bmjopen-2015-009417.

7.

Cystatin C- and Creatinine-Based Estimates of Glomerular Filtration Rate in Dapagliflozin Phase 3 Clinical Trials.

Mende C, Katz A.

Diabetes Ther. 2016 Mar;7(1):139-51. doi: 10.1007/s13300-016-0158-y. Epub 2016 Feb 22.

8.

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.

Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I.

Cardiovasc Diabetol. 2016 Feb 19;15:37. doi: 10.1186/s12933-016-0356-y.

9.

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.

Yavin Y, Mansfield TA, Ptaszynska A, Johnsson K, Parikh S, Johnsson E.

Diabetes Ther. 2016 Mar;7(1):125-37. doi: 10.1007/s13300-015-0150-y. Epub 2016 Jan 12.

10.

Empagliflozin in the treatment of type 2 diabetes: evidence to date.

Shubrook JH, Bokaie BB, Adkins SE.

Drug Des Devel Ther. 2015 Oct 30;9:5793-803. doi: 10.2147/DDDT.S69926. eCollection 2015. Review.

11.

Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.

Lopez JM, Macomson B, Ektare V, Patel D, Botteman M.

Am Health Drug Benefits. 2015 Sep;8(6):309-18.

12.

Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.

Yamada K, Nakayama H, Yoshinobu S, Kawano S, Tsuruta M, Nohara M, Hasuo R, Akasu S, Tokubuchi I, Wada N, Hirao S, Iwata S, Kaku H, Tajiri Y.

J Diabetes Investig. 2015 Nov;6(6):699-707. doi: 10.1111/jdi.12370. Epub 2015 Jun 20.

13.

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.

Fioretto P, Giaccari A, Sesti G.

Cardiovasc Diabetol. 2015 Oct 17;14:142. doi: 10.1186/s12933-015-0297-x. Review.

14.

Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.

Abdul-Ghani MA, Norton L, DeFronzo RA.

Am J Physiol Renal Physiol. 2015 Dec 1;309(11):F889-900. doi: 10.1152/ajprenal.00267.2015. Epub 2015 Sep 9. Review.

PMID:
26354881
15.

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.

Chao EC.

Clin Diabetes. 2014 Jan;32(1):4-11. doi: 10.2337/diaclin.32.1.4.

16.

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E.

Diabetes Care. 2015 Sep;38(9):1730-5. doi: 10.2337/dc15-0355. Epub 2015 Jul 15.

17.

The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.

Brunton SA.

Int J Clin Pract. 2015 Oct;69(10):1071-87. doi: 10.1111/ijcp.12675. Epub 2015 Jul 5. Review.

18.

Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes.

Hinnen D.

Ther Adv Endocrinol Metab. 2015 Jun;6(3):92-102. doi: 10.1177/2042018815575273. Review.

19.

Short commentary on empagliflozin and its potential clinical impact.

Hinnen D.

Ther Adv Endocrinol Metab. 2015 Apr;6(2):68-81. doi: 10.1177/2042018815578599. Review.

20.

Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options.

Cornell S.

Ther Clin Risk Manag. 2015 Apr 16;11:621-32. doi: 10.2147/TCRM.S67387. eCollection 2015. Review.

Items per page

Supplemental Content

Write to the Help Desk